Skip to main content

Table 3 Distribution of cardiac outcomes at baseline and 30 days after study initiation across different categories hs-troponin

From: Is high sensitive-troponin I a reliable biomarker for cardiac injury in methadone toxicity? A prospective cross-sectional study

Endpoint Hs-troponin positive (n = 12) P* Hs-troponin negative (n = 48) P* P Pƪ
Baseline After 30 days Baseline After 30 days
LVEF (%) 43.1 ± 15.4 43.7 ± 21.6 0.878 55 55.3 ± 1.2 0.083 < 0.001 < 0.001
Diastolic dysfunction (%) 3 (25) 2 (17) 0.317 4 (8) 4 (8) 0.346 0.108 0.389
Regional wall motion abnormalities (%) 5 (42) 3 (25) 0.483 0 (0) 2 (4) 0.511 < 0.001 0.020
LV size dilation (%) 5 (42) 2 (17) 0.375 0 0 1.00 < 0.001 0.004
Mitral regurgitation (%) 6 (50) 5 (42) 0.157 10 (63) 10 (21) 0.125 0.041 0.136
Tricuspid regurgitation (%) 6 (50) 4 (33) 0.572 7 (15) 7 (15) 0.553 0.008 0.133
Pulmonary arterial pressure (mmHg) 33.3 ± 9.3 32.9 ± 8.9 0.586 26.9 ± 5.02 28.9 ± 5.9 0.014 0.002 0.051
  1. Hs-Troponin high sensitive troponin, LVEF left ventricular ejection fraction, LV left ventricle
  2. * P value between baseline and after 30 days
  3. P value between hs-troponin positive and negative group at baseline
  4. ƪ P value between hs-troponin positive and negative group after 30 days